Table 2.
Achievement of KDIGO treatment targets by gender
| Treatment targets | Women (%) | Men (%) | P-value* |
|---|---|---|---|
| spKt/V >1.2 | 98.5 | 95.6 | <0.01 |
| URR ≥70% | 91.2 | 90.5 | NS |
| Treatment time ≥12 h/week | 92.2 | 95.0 | <0.05 |
| Prescribed Qb ≥300 mL/min | 93.0 | 94.8 | NS |
| Treated blood volume ≥1 L/kg BW | 90.5 | 89.6 | NS |
| Hb 10–12 g/dL | 70.2 | 65.2 | NS |
| Hb >12 g/dL | 11.9 | 17.7 | <0.01 |
| Ferritin ≥200 µg/L | 86.1 | 83.2 | NS |
| Ferritin ≥800 µg/L | 26.2 | 22.4 | NS |
| TSAT ≥20% | 81.2 | 81.7 | NS |
| TSAT ≥50% | 10.2 | 8.9 | NS |
| Treatment with ESA | 81.1 | 73.0 | 0.001 |
| Phosphorus ≤5.5 mg/dL | 80.3 | 83.2 | NS |
| Calcium ≤10.2 mg/dL | 97.5 | 98.6 | NS |
| PTH 150–600 pg/mL | 51.9 | 55.4 | NS |
| CVC (%) | 18.1 | 15.3 | NS |
| AV fistula (%) | 73.0 | 79.7 | <0.01 |
| S-Albumin ≥35 g/l | 87.4 | 91.5 | <0.05 |
| Charlson comorbidity index | NS | ||
| <7 | 44.4 | 44.6 | |
| 7–12 | 52.0 | 51.8 | |
| >12 | 3.6 | 3.6 |
*
Chi square analysis.